池村 辰之介

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Lung Neoplasms 48%
3. Adenocarcinoma of Lung 28%
4. osimertinib 25%
5. S 1 (combination) 25%
6. Mutation 24%
7. Carboplatin 19%
8. Multicenter Studies 17%
9. ErbB Receptors 17%
10. Lung 17%
11. Protein-Tyrosine Kinases 16%
12. Neoplasms 15%
13. Afatinib 15%
14. Squamous Cell Carcinoma 15%
15. Gefitinib 15%
16. Erlotinib Hydrochloride 14%
17. Therapeutics 13%
18. pembrolizumab 13%
19. Cell Line 13%
20. Cetuximab 12%
21. Retrospective Studies 12%
22. Small Cell Lung Carcinoma 12%
23. Survival 12%
24. Irinotecan 12%
25. Insertional Mutagenesis 12%
26. Adenocarcinoma 10%
27. Drug Therapy 10%
28. Japan 10%
29. Tumor Microenvironment 10%
30. AEE 788 9%
31. 7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile 9%
32. Exons 9%
33. Fibroblast Growth Factor 9 8%
34. navitoclax 8%
35. Lymph Nodes 8%
36. tissue-factor-pathway inhibitor 2 8%
37. Nivolumab 8%
38. Progression-Free Survival 8%
39. nedaplatin 8%
40. DNA Methylation 7%
41. Granisetron 7%
42. SARS Virus 7%
43. Platinum 7%
44. Lymphocyte Count 7%
45. Stromal Cells 7%
46. Pemetrexed 7%
47. Claudin-1 7%
48. Elderly 7%
49. Paclitaxel 6%